FCER2 and B-cell chronic lymphocytic leukemia: Lumiliximab is a genetically primatized, macaque human chimeric anti-CD23 IgG1κ mAb investigated for the treatment of relapsed CLL.22–25 It induces ADCC and CDC, and enhances apoptosis when combined with current or emerging CLL therapies including chlorambucil, fludarabine, alemtuzumab and rituximab.22 Byrd et al report the results of a phase 1–2 study, testing the R-FC regimen combined with lumiliximab in 31 patients with refractory/relapsed CLL.25 The patients had a median of 2 prior therapies (range 1–10) and 61% of them were treated with fludarabine.